TEM vs VCYT
TEM: Tempus AI leverages a massive library of multimodal clinical and molecular data to power AI-driven precision medicine for patients and researchers. VCYT: Veracyte is a genomic diagnostics company transforming cancer care with advanced, high-value testing platforms across the patient journey from diagnosis to monitoring.
Side-by-side fundamentals
| Metric | TEM | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $43.87 | $46.32 | |
| Market cap as of 2026-08-03 | $7.9B | $3.7B | |
| P/E as of 2026-08-03 | n/a | 33.02 | |
| PEG as of 2026-08-03 | -1.42 | 0.13 | TEM lower |
| Net margin as of 2026-08-03 | -22.2% | +20.4% | VCYT higher |
| Gross margin as of 2026-08-03 | +63.4% | +71.7% | VCYT higher |
| Operating margin as of 2026-08-03 | -20.6% | +19.6% | VCYT higher |
| ROE as of 2026-08-03 | -70.2% | +8.6% | VCYT higher |
| ROA as of 2026-08-03 | -14.6% | +8.0% | VCYT higher |
| Debt / equity as of 2026-08-03 | 2.96 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-08-03 | +69.8% | +17.3% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | +58.3% | +20.4% | TEM higher |
| Beta as of 2026-08-03 | 2.70 | 1.37 | |
| 1-year return as of 2026-07-31 close | -22.5% | +97.0% | VCYT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.